Transkaryotic Therapies (MM) News - TKTX | Aktien NASDAQ

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

CRISPR Therapeutics Proposes Changes to the Board of Directors

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP...

TKT Stockholders Approve Acquisition by Shire

TKT Stockholders Approve Acquisition by Shire CAMBRIDGE, Mass., July 27 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX...

TKT Confirms That Board of Directors Unanimously Recommends That Stockholders Approve Shire Transaction

TKT Confirms That Board of Directors Unanimously Recommends That Stockholders Approve Shire Transaction CAMBRIDGE, Mass., July 14...

TKT Issues Open Letter to Stockholders

TKT Issues Open Letter to Stockholders Board of Directors Urges TKT Stockholders to Vote 'FOR' Shire Transaction CAMBRIDGE, Mass., July 12...

TKT to Hold Special Meeting of Stockholders on July 27, 2005

TKT to Hold Special Meeting of Stockholders on July 27, 2005 CAMBRIDGE, Mass., June 27 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc...

TKT Reports Positive Top-Line Results of Hunter Syndrome Pivotal Trial

TKT Reports Positive Top-Line Results of Hunter Syndrome Pivotal Trial Primary Endpoint Achieves Statistical Significance CAMBRIDGE, Mass., June...

TKT Announces Expiration of Both Hart-Scott-Rodino Waiting Period and SEC Review Period of Preliminary Proxy Statement

TKT Announces Expiration of Both Hart-Scott-Rodino Waiting Period and SEC Review Period of Preliminary Proxy Statement CAMBRIDGE, Mass., June 13...

TKT Announces First Quarter 2005 Results

TKT Announces First Quarter 2005 Results CAMBRIDGE, Mass., May 5 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today...

TKT Assessing Impact of Fire at Manufacturing Facility

TKT Assessing Impact of Fire at Manufacturing Facility CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc...

TKT to Report First Quarter 2005 Financial Results on May 5, 2005

TKT to Report First Quarter 2005 Financial Results on May 5, 2005 CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Transkaryotic...

TKT Announces Agreement to be Acquired by Shire for $1.6 Billion

TKT Announces Agreement to be Acquired by Shire for $1.6 Billion CAMBRIDGE, Mass., April 21 /PRNewswire-FirstCall/ -- Tranksaryotic...

TKT Achieves GA-GCB Clinical Milestone

TKT Achieves GA-GCB Clinical Milestone GA-GCB, I2S and Dynepo Top-Line Results Expected in the Coming Months CAMBRIDGE, Mass., April 20...

TKT Announces Appointment of Eric Pauwels as Senior Vice President, Global Commercial Operations

TKT Announces Appointment of Eric Pauwels as Senior Vice President, Global Commercial Operations CAMBRIDGE, Mass., March 29...

New Website Offers Comprehensive Information on Hunter Syndrome

New Website Offers Comprehensive Information on Hunter Syndrome CAMBRIDGE, Mass., March 28 /PRNewswire-FirstCall/ -- Transkaryotic...

TKT to Present at Two Upcoming Healthcare Conferences

TKT to Present at Two Upcoming Healthcare Conferences CAMBRIDGE, Mass., March 24 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc...

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Transkaryotic Therapies (MM) (TKTX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

TKTX Nachrichten

CRISPR Therapeutics Proposes Changes to the Board of Directors

TKT Stockholders Approve Acquisition by Shire

TKT Confirms That Board of Directors Unanimously Recommends That Stockholders Approve Shire Transaction

TKT Issues Open Letter to Stockholders

TKT to Hold Special Meeting of Stockholders on July 27, 2005

TKT Reports Positive Top-Line Results of Hunter Syndrome Pivotal Trial

TKT Announces Expiration of Both Hart-Scott-Rodino Waiting Period and SEC Review Period of Preliminary Proxy Statement

TKT Announces First Quarter 2005 Results

TKT Assessing Impact of Fire at Manufacturing Facility

TKT to Report First Quarter 2005 Financial Results on May 5, 2005

TKT Announces Agreement to be Acquired by Shire for $1.6 Billion

TKT Achieves GA-GCB Clinical Milestone

TKT Announces Appointment of Eric Pauwels as Senior Vice President, Global Commercial Operations

New Website Offers Comprehensive Information on Hunter Syndrome

TKT to Present at Two Upcoming Healthcare Conferences

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Transkaryotic Therapies (MM) (TKTX) News

Transkaryotic Therapies (MM) (TKTX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

TKTX Nachrichten

CRISPR Therapeutics Proposes Changes to the Board of Directors

TKT Stockholders Approve Acquisition by Shire

TKT Confirms That Board of Directors Unanimously Recommends That Stockholders Approve Shire Transaction

TKT Issues Open Letter to Stockholders

TKT to Hold Special Meeting of Stockholders on July 27, 2005

TKT Reports Positive Top-Line Results of Hunter Syndrome Pivotal Trial

TKT Announces Expiration of Both Hart-Scott-Rodino Waiting Period and SEC Review Period of Preliminary Proxy Statement

TKT Announces First Quarter 2005 Results

TKT Assessing Impact of Fire at Manufacturing Facility

TKT to Report First Quarter 2005 Financial Results on May 5, 2005

TKT Announces Agreement to be Acquired by Shire for $1.6 Billion

TKT Achieves GA-GCB Clinical Milestone

TKT Announces Appointment of Eric Pauwels as Senior Vice President, Global Commercial Operations

New Website Offers Comprehensive Information on Hunter Syndrome

TKT to Present at Two Upcoming Healthcare Conferences

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen